Nothing Special   »   [go: up one dir, main page]

EP1017856A1 - Method and kit for evaluation of hiv mutations - Google Patents

Method and kit for evaluation of hiv mutations

Info

Publication number
EP1017856A1
EP1017856A1 EP98944941A EP98944941A EP1017856A1 EP 1017856 A1 EP1017856 A1 EP 1017856A1 EP 98944941 A EP98944941 A EP 98944941A EP 98944941 A EP98944941 A EP 98944941A EP 1017856 A1 EP1017856 A1 EP 1017856A1
Authority
EP
European Patent Office
Prior art keywords
seq
primer
sequencing
hiv
pair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98944941A
Other languages
German (de)
French (fr)
Inventor
James M. Dunn
Jean-Michel Lacroix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Visible Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/938,641 external-priority patent/US6007983A/en
Application filed by Visible Genetics Inc filed Critical Visible Genetics Inc
Publication of EP1017856A1 publication Critical patent/EP1017856A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Definitions

  • SSCP 'single-stranded conformational polymorphism
  • ddF dideoxy-fingerprinting
  • WO 97/23650 discloses the evaluation of the allelic type of a polymorphic genetic locus by evaluation of less than all four of the bases of a nucleotide sequence.
  • the invention of that application is exemplified with respect to determination of allelic type for HLA and typing o ⁇ Chlamydial strains. There is no specific disclosure of probes for use in evaluation of HIV types.
  • This application relates to a particular series of tests which can be useful alone or as part of a hierarchical testing protocol for the detection and characterization of human immunodeficiency virus (HIV).
  • HAV human immunodeficiency virus
  • the method of the invention provides a streamlined, hierarchical method for obtaining information about the allelic type of a sample of genetic material derived from an HIV-infected sample. It has been determined that 93 to 95% of the known mutational variants of the protease and reverse transcriptase genes of HIV can be determined by evaluating the positions of the A and T nucleotides within the sample. Thus, a substantial fraction of all mutational variations can be unequivocally identified by performing two initial sequencing reactions on the sample in which only ddA and ddT are used as chain terminators.
  • a second test is performed in which the sequence is determined in the 3'-direction for all four bases. This test will identify substantially all of the remaining samples. For those for which an ambiguity remains, however, a final test in which the sequence of the sample is determined in both the 3' and 5 -direction for all four bases is performed.
  • reagents suitable for performing the three tests within the hierarchy are suitably packaged as a kit containing two or more sub- kits.
  • the first sub-kit contains reagents for performing A and T sequencing.
  • the addition sub-kit(s) contains reagents for performing a four-base sequence determination on one or both strands of the target DNA.
  • Fig. 1 shows a schematic representation of the invention
  • Figs. 2A and 2B shows the bases which are changed in known mutations of the protease and reverse transcriptase genes of HIV- 1.
  • Allele refers to a specific version of a nucleotide sequence at a polymorphic genetic locus.
  • Polymorphic site means a given nucleotide location in a genetic locus which is variable within a population.
  • Gene or “Genetic locus” means a specific nucleotide sequence within a given genome.
  • location or “position” of a nucleotide in a genetic locus means the number assigned to the nucleotide in the gene, generally taken from the cDNA sequence or the genomic sequence of the gene.
  • the nucleotides Adenine. Cytosine. Guanine and Thymine are sometimes represented by their designations of A, C, G or T, respectively. Dideoxynucleotides which are used as chain terminators are abbreviated as ddA. ddC. ddG and ddT.
  • each of the four sequencing reactions generates a plurality of primer extension products, all of which end with a specific type of dideoxynucleotide.
  • Each lane on the electrophoresis gel thus reflects the positions of one type of base in the extension product, but does not reveal the order and type of nucleotides intervening between the bases of this specific type.
  • the information provided by the four lanes is therefore combined in known sequencing procedures to arrive at a composite picture of the sequence as a whole.
  • the sequence of a good portion of the diagnostically relevant protease and reverse transcriptase genes is obtained in three steps: 1) cDNA is generated from the RNA present in the sample, and amplified, preferably across a region extending from 6 codons before the protease up to codon 335 of the reverse transcriptase of HIV- 1 (the primer regions are not included in this range). 2) Sequencing reactions are performed at one or more of several hierarchical levels . 3) Finally, the sequencing ladders are analyzed, preferably using the OpenGeneTM System: the Micro GeneBlasterTM DNA Sequencer, GeneObjectsTM and GeneLibrarianTM Softwares.
  • Fig. 1 shows one embodiment of the method of the invention schematically. As shown, an RNA sample is obtained and treated by reverse transcriptase-PCR (RT-PCR).
  • RT-PCR reverse transcriptase-PCR
  • This amplicon is then combined with a master sequencing mixture containing buffer (260 mM Tris-HCL, pH 8.3; 32.5 mM MgCl 2 ) and a polymerase enzyme such as
  • Taq FS Perkin Elmer/Applied Biosystems Cat No. 402070
  • This polymerase has a high rate of incorporartion of dideoxynucleotide relateive to the incorporation rate of, for example, conventional Taq polymerase.
  • This mixture is used as stock in the subsequent reactions.
  • the first sequencing reaction performed in the method of the invention is a single-base sequencing reaction performed using either ddA or ddT in the sequencing mixture. This reaction is performed on the protease gene using the following primers: forward primer:
  • reverse primers which may be used are:
  • both the forward and reverse primers are preferably each labeled with one of the two dyes.
  • Forward and reverse sequencing fragments are then generated by thermally cycling the sample through multiple thermal cycles in the presence of either ddA or ddT. Analysis of the sequencing fragments produced using gel electrophoresis will allow the determination of the positions of both A and T bases. As shown in Figs. 2A and B, knowledge of the position of the A and T bases will identify 95% of all known mutational variants within the reverse transcriptase gene and 93% of the variants within the protease gene.
  • the allelic type of majority of samples can be identified. If the sequencer employed is only capable of evaluating a single base, then two reaction need to be employed. These may be a forward and backwards sequencing reaction both employing the same chain terminator (ddA or ddT), or two reaction performed in the same direction, one with ddA and one with ddT so that the positions of A and T bases are determined. These sequencing reactions can be employed using the same primers discussed above.
  • a further sequencing reaction is performed on the sample stock to determine the positions of all four bases.
  • this is a sequencing reaction of intermediate complexity, involving the sequencing of one of the two strands of the
  • DNA or a combination of the two strands making up one complete linear sequence This can be done using the same primers identified above to obtain sequencing fragments.
  • sequencing of both strands may be performed. Again, the same sequencing primers identified above are used. Forward and reverse sequencing fragments can be produced in a single reaction using distinctively labeled forward and reverse primers, or in separate reactions depending on the nature of the detection system being employed.
  • kits suitable for practicing the method of the invention are suitably packaged in kit form.
  • the invention provides a kit for analyzing the genetic type of an HIV-1 gene in a sample using a hierarchical assay comprising, in separately packed combinations:
  • a first subkit for performing A and T sequencing on HIV- 1 comprising a plurality of A or T terminations mixtures, or both A and T termination mixtures, but no G termination mixture or C termination mixture, each of said A and T termination mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label;
  • a second subkit for performing four base sequencing on HIV-1 comprising a plurality of A, C, G and T terminations mixtures, each of said termination mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label. Additional subkits for performing four base sequencing may be included when intermediate and final assays on one strand and both strands are desired.
  • termination mixture refers to a mixture containing a mixture of the four deoxunucleotide triphosphates (dATP, dCTP, dGTP, and dTTP), one species of chain terminating dideoxynucleotide (ddATP. ddCTP, ddGTP or ddTTP) and the appropriate sequencing primers.
  • the subkit for performing A and T sequencing on HIV-1 may also be provided separately for performing the initial determination of only the A and T nucleotides.
  • a preferred kit of this type whether provided separately or as part of a kit for performing a hierarchical assay has primer pairs in which each primer is labeled with a different an spectroscopically distinguishable fluorescent dye, such as Cy5.0 and Cy5.5 and includes only one of the two possible types of termination mixtures, for example just the T termination mixture.
  • Example 1 The variety or sub-type of HIV can be determined by Single Track Sequencing of a sample which has been amplifed by RT-PCR.
  • a reaction mixture is prepared as follows: 3 ul bound beads
  • the sequencing primer employed is the non-biotinylated primer of the sequencing template amplification reaction, but this time it is labeled with a detectable label.
  • the preferred label for detection on the MicroGene Blaster is Cy5.5 linked to the 5' nucleotide of the primer.
  • a single chain termination reaction mixture in this case for the T nucleotide, is prepared by combining 750 uM of each of dATP, dCTP, dGTP and dTTP; and 2.5 uM of ddTTP. 3 ul of the termination reaction mix is place in a tube. 3 ul of the sequencing reaction mixture is added. An oil overlay is added and the single track reaction mixture is heated to 95 C for 2 mins in a PTC- 100 Programmable Thermal Controller (MJ Research, Inc.) or Robocycler Gradient 96 (Stratagene) before being thermally processed for 25 cycles (or fewer if found to be satisfactory) as follows:
  • the sample After a final extension at 70 °C for 5 min the sample is denatured at 95 °C for 30 sees and left on ice.
  • the sample is mixed with 6 ul of STOP/Loading buffer containing 100%) formamide and 5 mg/ml dye such as dextran blue. 1.5 ul of the mixture is loaded on a single lane of a MICROGENE BLASTER
  • reaction products are separated by electrophoresis through a denaturing polyacrylamide gel.
  • the reaction products are detected and presented with GENEOBJECTS software (Visible Genetics Inc., Toronto).
  • GENEOBJECTS software Visible Genetics Inc., Toronto.
  • the finger-print or barcode of the reaction products is compared to all known varieties of the pathogen nucleic acid sequence. An exact match is sought. If only one match is found, that subtype or variety is positively identified. If the patient sample had mixed varieties the result may show a heterogenous mix. The members of the heterogenous mix and relative quantities may be determined.
  • EXAMPLE 2 The variety or sub-type of the pathogen can be determined using CLIPTM sequencing methodology. In this method the sequence of both the sense strand and antisense strand of the protease gene of HIV- 1 may be obtained in a one step reaction as follows.
  • 13X reaction buffer consists of Tris-HCL 260 mM pH 8.3, MgCl 2 39 mM.
  • PR526 CCATTCCTGG CTTTAATTTT ACTGG Seq ID No. 22
  • results from each primer were compared to the known protease gene sequences of HIV- 1 and -2 by GENELIBRARIAN (a component of GENEOBJECTS (Visible Genetics Inc., Toronto).
  • the sub-type of HIV- 1 or HIV-2 is determined, and the presence of drug resistance codons is determined. Once the sequence of the HIV sub-type(s) is determined, it is reported to the patient file along with the quantitation data.
  • EXAMPLE 3 The RT-PCR is done on the HIV-1 RNA using the TitanTM One Tube RT-PCR System from Boehringer Mannheim. This RT-PCR is done on the RNA preparation obtained using the AmplicorTM HIV Monitor Test from Roche Diagnostic. It can also be done on the RNA extract for the NucliSenseTM (formerly known as NASBA) HIV Viral
  • RNA sample from the Amplicor HIV Monitor Test and keep on ice. This is the material obtained at step 14 of the section B "Specimen Preparation”. If using RNA prepared for the NucliSense Assay, proceed the same way: thaw it and keep it on ice.
  • RNA sample
  • EXAMPLE 4 To determine the sequence of amplicon, 7 ⁇ l of each terminator mix (32 mixes when using a single dye instrument, 4 when using a two dye instrument) are combined with a 5 ul of a master mix as follows: MASTER MIX (single dye system))
  • MASTER MIX two-dye system 18.5 ⁇ l of buffer 72.5 ⁇ l of sterile water
  • thermocylcing reaction The following is the programming for the PTC-200:
  • Termination mix for the protease - one dye system 1.07 ⁇ M ddATP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • C-Mix 2.14 ⁇ M ddCTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • G-Mix 2.14 ⁇ M ddGTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers
  • T-Mix 2.14 ⁇ M ddTTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • Termination mix for the first region of reverse transcriptase - (one dye system)
  • A-Mix 1.07 ⁇ M ddATP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • C-Mix 2.14 ⁇ M ddCTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • each of forward and reverse primers G-Mix 2.14 ⁇ M ddGTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • each of forward and reverse primers T-Mix 2.14 ⁇ M ddTTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers One primer of eachpair is labeled.
  • A-Mix 1.07 ⁇ M ddATP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • C-Mix 2.14 ⁇ M ddCTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • each of forward and reverse primers G-Mix 2.14 ⁇ M ddGTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • T-Mix 2.14 ⁇ M ddTTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • One primer is each pair is labeled.
  • A-Mix 1.07 ⁇ M ddATP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • C-Mix 2.14 ⁇ M ddCTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers
  • G-Mix 2.14 ⁇ M ddGTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • T-Mix 2.14 ⁇ M ddTTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • A-Mix 1.07 ⁇ M ddATP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers
  • C-Mix 2.14 ⁇ M ddCTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers
  • G-Mix 2.14 ⁇ M ddGTP; 643 ⁇ M dATP; 643 ⁇ M dCTP: 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers
  • T-Mix 2.14 ⁇ M ddTTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers
  • Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.
  • A-Mix 1.07 ⁇ M ddATP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers
  • C-Mix 2.14 ⁇ M ddCTP; 643 ⁇ M dATP; 643 ⁇ M dCTP: 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • G-Mix 2.14 ⁇ M ddGTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • each of forward and reverse primers T-Mix 2.14 ⁇ M ddTTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.
  • Second reverse transcriptase region A-Mix 1.07 ⁇ M ddATP; 643 ⁇ M dATP; 643 ⁇ M dCTP: 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • C-Mix 2.14 ⁇ M ddCTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • G-Mix 2.14 ⁇ M ddGTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers
  • T-Mix 2.14 ⁇ M ddTTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.
  • A-Mix 1.07 ⁇ M ddATP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP; 330 nM each of forward and reverse primers
  • C-Mix 2.14 ⁇ M ddCTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • G-Mix 2.14 ⁇ M ddGTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • T-Mix 2.14 ⁇ M ddTTP; 643 ⁇ M dATP; 643 ⁇ M dCTP; 643 ⁇ M dGTP; 643 ⁇ M dTTP;
  • Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A streamlined, hierarchical method for obtaining information about the allelic type of a sample of genetic material derived from an HIV-infected sample relies on the observation that 93-95 % of the known mutational variants of the reverse transcriptase and protease genes of HIV-1 can be determined by evaluating the positions of the A and T nucleotides within the sample. Thus, a substantial fraction of all mutational variations can be unequivocally identified by performing two initial sequencing reactions on the sample in which only ddA and ddT are used as chain terminators. For the small fraction of samples which are not identifiable based on the positions of these two bases, a second test is performed in which the sequence is determined in the 3'-direction for all four bases. This test will identify substantially all of the remaining samples. For those for which an ambiguity remains, however, a final test in which the sequence of the sample is determined in both the 3' and 5-direction for all four bases in performed. To perform the method, reagents suitable for performing the three tests within the hierarchy are suitably packaged as a kit containing two or more sub-kits. The first sub-kit contains reagents for performing A and T sequencing. The additional sub-kits contain reagents for performing a four-base sequence determination on one or both strands of the target DNA.

Description

METHOD AND KIT FOR EVALUATION OF HIV MUTATIONS
BACKGROUND OF THE INVENTION
Genetic testing to determine the presence of or a susceptibility to a disease condition offers incredible opportunities for improved medical care, and the potential for such testing increases almost daily as ever increasing numbers of disease-associated genes and/or mutations are identified. A major hurdle which must be overcome to realize this potential, however, is the high cost of testing. This is particularly true in the case of highly polymorphic genes where the need to test for a large number of variations may make the test procedure appear to be so expensive that routine testing can never be achieved.
Testing for changes in DNA sequence can proceed via complete sequencing of a target nucleic acid molecule, although many persons in the art believe that such testing is too expensive to ever be routine. Changes in DNA sequence can also be detected by a technique called 'single-stranded conformational polymorphism" ( "SSCP") described by Orita et al., Genomics 5: 874-879 (1989), or by a modification thereof referred to a dideoxy-fingerprinting ("ddF") described by Sarkar et al., Genomics 13: 4410443 (1992). SSCP and ddF both evaluate the pattern of bands created when DNA fragments are electrophoretically separated on a non-denaturing electrophoresis gel. This pattern depends on a combination of the size of the fragments and of the three-dimensional conformation of the undenatured fragments. Thus, the pattern cannot be used for sequencing, because the theoretical spacing of the fragment bands is not equal. The hierarchical assay methodology described in US Patent No. 5,545,527 and
International Patent Publication No. WO 96/07761. which are incorporated herein by reference, provides a mechanism for systematically reducing the cost per test by utilizing a series of different test methodologies which may have significant numbers of results incorrectly indicating the absence of a genetic sequence of interest, but which rarely if ever yield a result incorrectly indicating the presence of such a genetic sequence. The tests employed in the hierarchy may frequently be combinations of different types of molecular tests, for examples combinations of immunoassays, oligonucleotide probe hybridization tests, oligonucleotide fragment analyses, and direct nucleic acid sequencing. International Patent Publication No. WO 97/23650 discloses the evaluation of the allelic type of a polymorphic genetic locus by evaluation of less than all four of the bases of a nucleotide sequence. The invention of that application is exemplified with respect to determination of allelic type for HLA and typing oϊChlamydial strains. There is no specific disclosure of probes for use in evaluation of HIV types.
This application relates to a particular series of tests which can be useful alone or as part of a hierarchical testing protocol for the detection and characterization of human immunodeficiency virus (HIV).
SUMMARY OF THE INVENTION The method of the invention provides a streamlined, hierarchical method for obtaining information about the allelic type of a sample of genetic material derived from an HIV-infected sample. It has been determined that 93 to 95% of the known mutational variants of the protease and reverse transcriptase genes of HIV can be determined by evaluating the positions of the A and T nucleotides within the sample. Thus, a substantial fraction of all mutational variations can be unequivocally identified by performing two initial sequencing reactions on the sample in which only ddA and ddT are used as chain terminators. For the small fraction of samples which are not identifiable based on the positions of these two bases, a second test is performed in which the sequence is determined in the 3'-direction for all four bases. This test will identify substantially all of the remaining samples. For those for which an ambiguity remains, however, a final test in which the sequence of the sample is determined in both the 3' and 5 -direction for all four bases is performed. To perform the method of the invention, reagents suitable for performing the three tests within the hierarchy are suitably packaged as a kit containing two or more sub- kits. The first sub-kit contains reagents for performing A and T sequencing. The addition sub-kit(s) contains reagents for performing a four-base sequence determination on one or both strands of the target DNA. One-stranded sequence determination could be performed all in the 3'-direction, all in the 5'-direction, or as a combination of the two strands. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows a schematic representation of the invention; and Figs. 2A and 2B shows the bases which are changed in known mutations of the protease and reverse transcriptase genes of HIV- 1.
DETAILED DESCRIPTION OF THE INVENTION While the terminology used in this application is standard within the art, the following definitions of certain terms are provided to assure clarity.
1. "Allele" refers to a specific version of a nucleotide sequence at a polymorphic genetic locus.
2. "Polymorphic site" means a given nucleotide location in a genetic locus which is variable within a population.
3. "Gene" or "Genetic locus" means a specific nucleotide sequence within a given genome. 4. The "location" or "position" of a nucleotide in a genetic locus means the number assigned to the nucleotide in the gene, generally taken from the cDNA sequence or the genomic sequence of the gene.
5. The nucleotides Adenine. Cytosine. Guanine and Thymine are sometimes represented by their designations of A, C, G or T, respectively. Dideoxynucleotides which are used as chain terminators are abbreviated as ddA. ddC. ddG and ddT.
While it has long been apparent to persons skilled in the art that knowledge of the identity of the base at a particular location within a polymorphic genetic locus may be sufficient to determine the allelic type of that locus, this knowledge has not led to any modification of sequencing procedures. Rather, the knowledge has driven development of techniques such as allele-specific hybridization assays, and allele-specific ligation assays.
Despite the failure of the art to recognize the possibility, however, it is not always necessary to determine the sequence of all four nucleotides of a polymorphic genetic locus in order to determine which allele is present in a specific patient sample. As disclosed generally in International Patent Publication No. WO 97/23650, certain alleles of a genetic locus may be distinguishable on the basis of identification of the location of less than four, and often only one nucleotide. This finding allows the development of the present method for improved allele identification within the highly polymorphic HIV genome.
Traditionally, if sequencing were going to be used to evaluate the allelic type of a polymorphic gene, four dideoxy nucleotide "sequencing" reactions of the type described by Sanger et al. (Proc. Natl. Acad. Sci. USA 74: 5463-5467 (1977)) would be run on the sample concurrently, and the products of the four reactions would then be analyzed by polyacrylamide gel electrophoresis. (see Chp 7.6, Current Protocols in Molecular Biology, Eds. Ausubel, F.M. et al, (John Wiley & Sons; 1995)) In this well- known technique, each of the four sequencing reactions generates a plurality of primer extension products, all of which end with a specific type of dideoxynucleotide. Each lane on the electrophoresis gel thus reflects the positions of one type of base in the extension product, but does not reveal the order and type of nucleotides intervening between the bases of this specific type. The information provided by the four lanes is therefore combined in known sequencing procedures to arrive at a composite picture of the sequence as a whole.
In the method of the invention the sequence of a good portion of the diagnostically relevant protease and reverse transcriptase genes is obtained in three steps: 1) cDNA is generated from the RNA present in the sample, and amplified, preferably across a region extending from 6 codons before the protease up to codon 335 of the reverse transcriptase of HIV- 1 (the primer regions are not included in this range). 2) Sequencing reactions are performed at one or more of several hierarchical levels . 3) Finally, the sequencing ladders are analyzed, preferably using the OpenGene™ System: the Micro GeneBlaster™ DNA Sequencer, GeneObjects™ and GeneLibrarian™ Softwares.
Fig. 1 shows one embodiment of the method of the invention schematically. As shown, an RNA sample is obtained and treated by reverse transcriptase-PCR (RT-
PCR) to produce an amplicon of approximately 1.3 kbase pairs spanning the protease and reverse transcriptase genes of the HIV genome from a target cell. This reaction can be performed using, for example, the TITAN™ One-Tube RT-PCR system from Boehringer Mannheim (Cat. No. 1 855 476 or 1 882 382) using the following primers: CAGAARCAGG AGCHGAWAGA CA (forward) Seq ID No.1
CTAYTARGTC TTTTG TGGG TCATA (reverse) Seq ID No.2 Other primers which could be used at this step include: forward primers:
AAGCAGGAGC CGATAGACAA GG Seq ID No.3
AAGCAGGAGC TGAAAGACAG GG Seq ID No.4 AAGCAGGAGC AGA7AAGACAA GG Seq ID No.5 reverse primers:
CAGAAGCAGG AGCCGA AGA CA Seq ID No.6
CTATTAAGTC TTTTGATGGG TCATA Seq ID No. 7
This amplicon is then combined with a master sequencing mixture containing buffer (260 mM Tris-HCL, pH 8.3; 32.5 mM MgCl2) and a polymerase enzyme such as
Taq FS (Perkin Elmer/Applied Biosystems Cat No. 402070) This polymerase has a high rate of incorporartion of dideoxynucleotide relateive to the incorporation rate of, for example, conventional Taq polymerase. This mixture is used as stock in the subsequent reactions. The first sequencing reaction performed in the method of the invention is a single-base sequencing reaction performed using either ddA or ddT in the sequencing mixture. This reaction is performed on the protease gene using the following primers: forward primer:
GCCGATAGAC AAGGAACTG Seq ID No. 8 reverse primer
ACTTTTGGGC CATCCATTCC T Seq ID No. 9
Alternate reverse primers which may be used are:
ACTTTTGGGC CATCCATCCC T Seq ID No.10
ACCTTTGGTC CATCCATTCC T Seq ID No.11
For the reverse transcriptase gene, three sets of primers are used as follows:
RT1 Primers forward:
GTTAAACAAT GGCCATTGAC AGAAGA Seq ID No. 12 reverse:
GGAATATTGC TGGTGATCCT TTCC Seq ID No. 13 alternate forward:
GTTAAACAAT GGCCATTGAC AG Seq ID No. 14
RT2 Primers forward:
ATTAGATATC AGTACAATGT GC Seq ID No. 15 reverse:
TCTGTATGTC ATTGACAGTC CAGC Seq ID No. 16 alternate reverse: TCTGTATATC ATTGACAGTC CAGT Seq ID No. 17
TCTGTATATC ATTGACAGTC CAGC Seq ID No. 18
TTCTGTATGT CATTGACAGT CCAGC Seq ID No. 19
RT3 Primers forward:
GACTTAGAAA TAGGGCAGCA TAGA Seq ID No. 20 reverse:
ATTAAGTCTT TTGATGGGTC ATAA Seq ID No.21
When a sequencing device is employed which is capable of detecting and distinguishing two different fluorescent dyes (such as, for example, the ABI Prism Models 377, 310 or 373 or LiCor IR2 System), both the forward and reverse primers are preferably each labeled with one of the two dyes. Forward and reverse sequencing fragments are then generated by thermally cycling the sample through multiple thermal cycles in the presence of either ddA or ddT. Analysis of the sequencing fragments produced using gel electrophoresis will allow the determination of the positions of both A and T bases. As shown in Figs. 2A and B, knowledge of the position of the A and T bases will identify 95% of all known mutational variants within the reverse transcriptase gene and 93% of the variants within the protease gene. Thus, by performing a single reaction, the allelic type of majority of samples can be identified. If the sequencer employed is only capable of evaluating a single base, then two reaction need to be employed. These may be a forward and backwards sequencing reaction both employing the same chain terminator (ddA or ddT), or two reaction performed in the same direction, one with ddA and one with ddT so that the positions of A and T bases are determined. These sequencing reactions can be employed using the same primers discussed above.
If the type of the HIV present in the sample cannot determined based upon the results of the first reaction, then a further sequencing reaction is performed on the sample stock to determine the positions of all four bases. Preferably, this is a sequencing reaction of intermediate complexity, involving the sequencing of one of the two strands of the
DNA or a combination of the two strands making up one complete linear sequence. This can be done using the same primers identified above to obtain sequencing fragments.
Finally, if the intermediate test fails to provide unambiguous identification of the DNA type, sequencing of both strands may be performed. Again, the same sequencing primers identified above are used. Forward and reverse sequencing fragments can be produced in a single reaction using distinctively labeled forward and reverse primers, or in separate reactions depending on the nature of the detection system being employed.
Reagents suitable for practicing the method of the invention are suitably packaged in kit form. Thus, the invention provides a kit for analyzing the genetic type of an HIV-1 gene in a sample using a hierarchical assay comprising, in separately packed combinations:
(a) a first subkit for performing A and T sequencing on HIV- 1 , comprising a plurality of A or T terminations mixtures, or both A and T termination mixtures, but no G termination mixture or C termination mixture, each of said A and T termination mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label; and
(b) a second subkit for performing four base sequencing on HIV-1 comprising a plurality of A, C, G and T terminations mixtures, each of said termination mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label. Additional subkits for performing four base sequencing may be included when intermediate and final assays on one strand and both strands are desired. As used herein, the term "termination mixture" refers to a mixture containing a mixture of the four deoxunucleotide triphosphates (dATP, dCTP, dGTP, and dTTP), one species of chain terminating dideoxynucleotide (ddATP. ddCTP, ddGTP or ddTTP) and the appropriate sequencing primers.
The subkit for performing A and T sequencing on HIV-1 may also be provided separately for performing the initial determination of only the A and T nucleotides. A preferred kit of this type, whether provided separately or as part of a kit for performing a hierarchical assay has primer pairs in which each primer is labeled with a different an spectroscopically distinguishable fluorescent dye, such as Cy5.0 and Cy5.5 and includes only one of the two possible types of termination mixtures, for example just the T termination mixture.
The following examples are included to illustrate aspects of the instant invention and are not intended to limit the invention in any way.
Example 1 The variety or sub-type of HIV can be determined by Single Track Sequencing of a sample which has been amplifed by RT-PCR.
A reaction mixture is prepared as follows: 3 ul bound beads
3 ul sequencing primer (30 ng total) 2 ul 13X sequencing buffer (260 mM Tris-HCL, pH 9.5, 39 mM MgCl2)
2 ul Thermo Sequenase (Amersham Life Sciences, Cleveland) ((diluted 1:10 from stock to 3.2 U/ul)
3 ul distilled H2O. Final Volume: 13 ul The sequencing primer employed is the non-biotinylated primer of the sequencing template amplification reaction, but this time it is labeled with a detectable label. The preferred label for detection on the MicroGene Blaster is Cy5.5 linked to the 5' nucleotide of the primer.
CCATTCCTGG CTTTAATTTT ACTGG Seq ID No. 22
The reaction mixture is kept on ice. A single chain termination reaction mixture, in this case for the T nucleotide, is prepared by combining 750 uM of each of dATP, dCTP, dGTP and dTTP; and 2.5 uM of ddTTP. 3 ul of the termination reaction mix is place in a tube. 3 ul of the sequencing reaction mixture is added. An oil overlay is added and the single track reaction mixture is heated to 95 C for 2 mins in a PTC- 100 Programmable Thermal Controller (MJ Research, Inc.) or Robocycler Gradient 96 (Stratagene) before being thermally processed for 25 cycles (or fewer if found to be satisfactory) as follows:
Annealing: 50 °C for 10 Sec.
Extension: 70°C for 30 Sec. Denaturation: 95°C for 30 Sec.
After a final extension at 70 °C for 5 min the sample is denatured at 95 °C for 30 sees and left on ice. The sample is mixed with 6 ul of STOP/Loading buffer containing 100%) formamide and 5 mg/ml dye such as dextran blue. 1.5 ul of the mixture is loaded on a single lane of a MICROGENE BLASTER
(Visible Genetics Inc.. Toronto) and reaction products are separated by electrophoresis through a denaturing polyacrylamide gel. The reaction products are detected and presented with GENEOBJECTS software (Visible Genetics Inc., Toronto). The finger-print or barcode of the reaction products is compared to all known varieties of the pathogen nucleic acid sequence. An exact match is sought. If only one match is found, that subtype or variety is positively identified. If the patient sample had mixed varieties the result may show a heterogenous mix. The members of the heterogenous mix and relative quantities may be determined.
EXAMPLE 2 The variety or sub-type of the pathogen can be determined using CLIP™ sequencing methodology. In this method the sequence of both the sense strand and antisense strand of the protease gene of HIV- 1 may be obtained in a one step reaction as follows.
Combine the following materials and mix well:
Concentration Volume
Sequencing fragment DNA 3 ul PR211*Cy5.5 Primer 10 uM 0.5 ul PR526*Cy5.0 Primer lO uM 0.5 ul diluted Thermosequenase Enzyme 3.2 U/ul 2 ul 13 X Reaction buffer 2 ul double distilled H20 5 ul
TOTAL VOLUME 13.0 ul
13X reaction buffer consists of Tris-HCL 260 mM pH 8.3, MgCl239 mM.
PR211 ATCACTCTTT GGCAACGACC Seq ID No. 23
PR526: CCATTCCTGG CTTTAATTTT ACTGG Seq ID No. 22
Place 3 ul of mixture into each of 4 tubes. Heat tubes to 94 CC for 5 mins then reduce temperature to 85°C. Add and mix 3 ul of an 85 °C dNTP/ddNTP solution containing 0.75 mM each dNTP and 2.5 uM of a chain terminating nucleotide triphosphate (ddNTP) (use a different ddNTP in each of the 4 tubes).
Treat the mixture to 60 cycles of the following thermal cycling reactions: 94 °C for 10 sec, 62 °C for 15 sec, 70 °C for 1 min. Upon completion, treat the mixture for a final 5 min at 70 °C and then store at 4°C until ready for loading. For viewing the reaction products, add an equal volume of stop/loading solution (95%) formamide plus a colored dye). Take 1.5 ul and load in a single lane of a two dye MicroGene Blaster automated
DNA sequencer (Visible Genetics Inc., Toronto). The reaction products from the both labeled primers are detected on the MICROGENE BLASTER as two separate traces, and displayed on GENEOBJECTS Software.
The base-called results from each primer were compared to the known protease gene sequences of HIV- 1 and -2 by GENELIBRARIAN (a component of GENEOBJECTS (Visible Genetics Inc., Toronto). The sub-type of HIV- 1 or HIV-2 is determined, and the presence of drug resistance codons is determined. Once the sequence of the HIV sub-type(s) is determined, it is reported to the patient file along with the quantitation data.
EXAMPLE 3 The RT-PCR is done on the HIV-1 RNA using the Titan™ One Tube RT-PCR System from Boehringer Mannheim. This RT-PCR is done on the RNA preparation obtained using the Amplicor™ HIV Monitor Test from Roche Diagnostic. It can also be done on the RNA extract for the NucliSense™ (formerly known as NASBA) HIV Viral
Load from Organon Teknica.
All the reagents, tubes, tips, and other material needs to be RNase-free. The recipe is made for 8 reactions (one strip of 8 tubes), including 10%> extra. Thaw the RNA sample from the Amplicor HIV Monitor Test and keep on ice. This is the material obtained at step 14 of the section B "Specimen Preparation". If using RNA prepared for the NucliSense Assay, proceed the same way: thaw it and keep it on ice.
Take a 0.2 ml sterile, RNase-free, centrifuge tube, RNase-free. and prepare the RT-PCR Master Mix I (enough for 8 tubes, including 10%> extra) by adding the following ingredient in the order listed: RT-PCR MASTER MIX I
35 μl of lOO mM DTT
13 μl of RNase-free dNTP @ 10 mM each dNTP 13 μl of forward PCR primer at 10 μM. 13 μl of reverse PCR primer at 10 μM
Take a 0.2 ml sterile, RNase-free, centrifuge tube, RNase-free, and prepare the RT-PCR Master Mix II (enough for 8 tubes, including 20%. extra) by adding the following ingredient in the order listed:
RT-PCR MASTER MIX II
60 μl of Titan 5X Buffer 5 μl of RNase Inhibitor @ 40 U/μl
10 μl of Titan Enzyme.
18 μl of RNase-free MgC12 at 25 mM.
7 μl of RNase-free water
Take one strip of 8 thin wall tubes. Add 8.5 μl of MASTER MIX I in each tube.
Add 11.5 μl of sample (RNA) to each tube. You may want to add a negative control per experiment. If using RNA extracted for the NucliSense Assay, dilute the sample 1 :5 in
RNase-free water and use 11.5 μl of this dilution.
Heat the RNA sample at 90°C for 3 min. using the program below:, cool at 50°C and add 10 μl of the MASTER MIX II in each tube (step 2 of the program below).
Be careful not to cross contaminate your samples.
Start the RT-PCR. Use the heated lid. When using the MJ-Plates. indicates that tubes are used when asked by the PTC-200. The following is the programming for the
PTC-200: Calculated
1= 90.0° for 3:00
2= 50.0° for 5:00
3= 42.0°, 1 :00:00
4= 94.0° for 3:00 5= 1.0 s to 94.0°
6= 94.0° for 0:20
7= 1.0 s to 57.0°
8= 57.0° for 0:30
9= 1.07s to 68.0° 10= 68.0° for 2:30 l l=Goto 5, 19 times 12= 1.07s to 94.0° 13= 94.0° for 0:20 14= 1.07s to 57.0° 15= 57.0° for 0:30 16= 1.07s to 68.0°
17= 68.0° for 3:00 18=Goto 12, 24 times 19= 68.0° for 7:00 20= 4.0° for ever 21=End
Store at -20°C or keep at 4°C and use immediately.
EXAMPLE 4 To determine the sequence of amplicon, 7 μl of each terminator mix (32 mixes when using a single dye instrument, 4 when using a two dye instrument) are combined with a 5 ul of a master mix as follows: MASTER MIX (single dye system))
37 μl of buffer (260 mM Tris-HCl, pH 8.3, 32.5 mM MgC12) 145 μl of sterile water. 8 μl of undiluted TAQ FS 12 U/μl.
10 μl of the PCR product from Example 3
MASTER MIX (two-dye system) 18.5 μl of buffer 72.5 μl of sterile water
4 μl of undiluted TAQ FS 12 U/μl
5 μl of the PCR product from Example 3
The two mixtures are mixed gently with a pipette tip. Add 8 μl of oil in each tube (optional), and start the thermocylcing reaction. The following is the programming for the PTC-200:
Calculated 1= 94.0° for 5:00 2= 1.07s to 94.0° 3= 94.0° for 0:20 4= 1.07s to 56.0° 5= 56.0° for 0:20
6= 1.07s to 70.0° 7= 70.0° for 1 :30 8=Goto 2, 47 times 9= 70.0° for 5:00 10= 4.0° for ever l l=End
The following master mixes are used in this example.
Termination mix for the protease - one dye system. A-Mix: 1.07 μM ddATP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
C-Mix: 2.14 μM ddCTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
G-Mix: 2.14 μM ddGTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers
T-Mix: 2.14 μM ddTTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
One primer in each pair is labeled.
Termination mix for the first region of reverse transcriptase - (one dye system)
A-Mix: 1.07 μM ddATP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
C-Mix: 2.14 μM ddCTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers G-Mix: 2.14 μM ddGTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers T-Mix: 2.14 μM ddTTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers One primer of eachpair is labeled.
Termination mix for the second region of reverse transcriptase (one dye system)
A-Mix: 1.07 μM ddATP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
C-Mix: 2.14 μM ddCTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers G-Mix: 2.14 μM ddGTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
T-Mix: 2.14 μM ddTTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
One primer is each pair is labeled.
Termination mix for the third region of the reverse transcriptase (single dye system)
A-Mix: 1.07 μM ddATP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
C-Mix: 2.14 μM ddCTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers
G-Mix: 2.14 μM ddGTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
T-Mix: 2.14 μM ddTTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers One dye in each reaction is labeled.
Termination mixes for two dye systems Protease
A-Mix: 1.07 μM ddATP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers
C-Mix: 2.14 μM ddCTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers
G-Mix: 2.14 μM ddGTP; 643 μM dATP; 643 μM dCTP: 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers
T-Mix: 2.14 μM ddTTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers
Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.
First RT region
A-Mix: 1.07 μM ddATP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers
C-Mix: 2.14 μM ddCTP; 643 μM dATP; 643 μM dCTP: 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
G-Mix: 2.14 μM ddGTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers T-Mix: 2.14 μM ddTTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.
Second reverse transcriptase region A-Mix: 1.07 μM ddATP; 643 μM dATP; 643 μM dCTP: 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
C-Mix: 2.14 μM ddCTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
G-Mix: 2.14 μM ddGTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers
T-Mix: 2.14 μM ddTTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.
Third reverse transcriptase region
A-Mix: 1.07 μM ddATP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP; 330 nM each of forward and reverse primers
C-Mix: 2.14 μM ddCTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
G-Mix: 2.14 μM ddGTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
T-Mix: 2.14 μM ddTTP; 643 μM dATP; 643 μM dCTP; 643 μM dGTP; 643 μM dTTP;
330 nM each of forward and reverse primers
Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.

Claims

CLAIMS 1. A method for determining the genetic type of HIV- 1 present in a
~> sample containing HIV- 1 , comprising the steps of
3 (a) determining the positions of just the A and T nucleotides within the
4 protease and reverse transcriptase genes and comparing these positions
5 to the positions of the A and T nucleotides in known genetic types;
6 (b) if step (a) does not provide an unambiguous identification performing a
7 further sequencing reaction in which the position of all four bases are
8 determined.
1 2. The method of claim 1, wherein the positions of just the A and T
2 nucieotides are determined by performing a cycled reaction that generates both forward
3 and reverse sequencing fragments using two primers, each primer labeled with a different
4 and distinguishable detectable label.
1 3. The method of claim 2, wherein the label is a fluorescent label.
1 4. A kit for performing A and T sequencing on an HIV-1 gene.
2 comprising
3 a plurality of A or T terminations mixtures, or both A and T termination mixtures, but no G termination mixture or C termination mixture, each of said A and T termination
5 mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIN-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label.
5. A kit for analyzing the genetic type of an HIN-1 gene in a sample using a hierarchical assay comprising, in separately packed combinations: (a) a first subkit for performing A and T sequencing on HIV-1 , comprising a plurality of A or T terminations mixtures, or both A and T termination mixtures, but no G termination mixture or C termination mixture, each of said A and T termination mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label; and (b) a second subkit for performing four base sequencing on HIV- 1 comprising a plurality of A, C, G and T terminations mixtures, each of said termination mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label.
6. The kit according to claim 4 or 5, wherein the primers include a primer pair for sequencing of the protease gene comprising a forward primer of the sequence GCCGATAGAC AAGGAACTG Seq ID No.8 and a reverse primer selected from among ACTTTTGGGC CATCCATTCC T Seq ID No.-9 ACTTTTGGGC CATCCATCCC T Seq ID No.10 and ACCTTTGGTC CATCCATTCC T . Seq ID No.11
7. The kit according to any of claims 4 to 6 , wherein the primers include a primer pair for sequencing of a portion of the reverse transcriptase gene comprising a forward primer selected from among GTTAAACAAT GGCCATTGAC AGAAGA Seq ID No.12 and GTTAAACAAT GGCCATTGAC AG Seq ID No.14 and a reverse primer having the sequence GGAATATTGC TGGTGATCCT TTCC. Seq ID No.13
8. The kit according to any of claims 4 to 7, wherein the primers include a primer pair for sequencing of a portion of the reverse transcriptase gene comprising a forward primer having the sequence ATTAGATATC AGTACAATGT GC Seq ID No.15 and a reverse primer selected from among TCTGTATGTC ATTGACAGTC CAGC Seq ID No.16 TCTGTATATC ATTGACAGTC CAGT Seq ID No.17 TCTGTATATC ATTGACAGTC CAGC Seq ID No.18 and TTCTGTATGT CATTGACAGT CCAGC. Seq ID No.19
9. The kit according to any of claims 4 to 8, wherein the primers include a primer pair for sequencing of a portion of the reverse transcriptase gene comprising a forward primer having the sequence GACTTAGAAA TAGGGCAGCA TAGA Seq ID No.20 and a reverse primer having the sequence ATTAAGTCTT TTGATGGGTC ATAA. Seq ID No.21
10. The kit according to any of claims 4-9, wherein the primers in each primer pair are labeled with different and spectroscopically distinguishable fluorescent labels.
EP98944941A 1997-09-26 1998-09-28 Method and kit for evaluation of hiv mutations Withdrawn EP1017856A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US938641 1986-12-05
US08/938,641 US6007983A (en) 1995-12-22 1997-09-26 Method and kit for evaluation of HIV mutations
PCT/CA1998/000913 WO1999016910A1 (en) 1997-09-26 1998-09-28 Method and kit for evaluation of hiv mutations

Publications (1)

Publication Number Publication Date
EP1017856A1 true EP1017856A1 (en) 2000-07-12

Family

ID=25471725

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98944941A Withdrawn EP1017856A1 (en) 1997-09-26 1998-09-28 Method and kit for evaluation of hiv mutations

Country Status (5)

Country Link
EP (1) EP1017856A1 (en)
JP (1) JP2001518313A (en)
AU (1) AU751471B2 (en)
CA (1) CA2302201A1 (en)
WO (1) WO1999016910A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265152B1 (en) * 1995-12-22 2001-07-24 Visible Genetics Inc. Method and kit for evaluation of HIV mutations
DE60043789D1 (en) 1999-07-09 2010-03-18 Gen Probe Inc HIV-1 detection by nucleic acid amplification
GB2395787A (en) * 1999-10-15 2004-06-02 Visible Genetics Inc Method and kit for evaluation of HIV mutations
GB2395007A (en) * 1999-10-15 2004-05-12 Visible Genetics Inc Method and kit for evaluation of HIV mutations
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
CA2731495C (en) * 2000-09-01 2015-02-03 Gen-Probe Incorporated Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations
KR101390072B1 (en) 2004-09-14 2014-04-30 아고스 쎄라퓨틱스, 인코포레이티드 Strain independent amplification of pathogens and vaccines thereto

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0403333A2 (en) * 1989-06-02 1990-12-19 Institut Pasteur Nucleotide sequences of retroviral genomes of types HIV-I, HIV-2 and SIV, their uses for the amplification of these genomes and diagnosis in vitro of these viral infections
WO1992016180A2 (en) * 1991-03-13 1992-10-01 Siska Diagnostics, Inc. Detection of 3'-azido-3'-deoxythymidine resistance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629153A (en) * 1990-01-10 1997-05-13 Chiron Corporation Use of DNA-dependent RNA polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays
EP1752545A3 (en) * 1991-12-23 2007-12-26 Novartis Vaccines and Diagnostics, Inc. HIV probes for use in solution phase sandwich hybridization assays
AU3094895A (en) * 1994-07-08 1996-02-09 Eleftherios Diamandis Method, reagents and kit for diagnosis and targeted screening for p53 mutations
US6013436A (en) * 1994-07-08 2000-01-11 Visible Genetics, Inc. Compositions and methods for diagnosis of mutation in the von Hippel-Lindau tumor suppressor gene
US5834189A (en) * 1994-07-08 1998-11-10 Visible Genetics Inc. Method for evaluation of polymorphic genetic sequences, and the use thereof in identification of HLA types
US5795722A (en) * 1997-03-18 1998-08-18 Visible Genetics Inc. Method and kit for quantitation and nucleic acid sequencing of nucleic acid analytes in a sample

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0403333A2 (en) * 1989-06-02 1990-12-19 Institut Pasteur Nucleotide sequences of retroviral genomes of types HIV-I, HIV-2 and SIV, their uses for the amplification of these genomes and diagnosis in vitro of these viral infections
WO1992016180A2 (en) * 1991-03-13 1992-10-01 Siska Diagnostics, Inc. Detection of 3'-azido-3'-deoxythymidine resistance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9916910A1 *

Also Published As

Publication number Publication date
CA2302201A1 (en) 1999-04-08
AU751471B2 (en) 2002-08-15
JP2001518313A (en) 2001-10-16
AU9249398A (en) 1999-04-23
WO1999016910A1 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
EP0907752B1 (en) Method for determination of nucleic acid sequences and diagnostic applications thereof
AU718670B2 (en) Method for evaluation of polymorphic genetic sequences, and the use thereof in identification of HLA types
US5599666A (en) Allelic ladders for short tandem repeat loci
US7914986B2 (en) Detection of amplicon contamination during PCR exhibiting two different annealing temperatures
EP0777747A1 (en) Nucleotide sequencing method
JPH05292968A (en) Improvement for nucleic acid amplification
WO1996030545A9 (en) Mutation detection by differential primer extension of mutant and wildtype target sequences
WO1996030545A1 (en) Mutation detection by differential primer extension of mutant and wildtype target sequences
US5910413A (en) Method and kit for amplification, sequencing and typing of classical HLA class I genes
US6265152B1 (en) Method and kit for evaluation of HIV mutations
US6007983A (en) Method and kit for evaluation of HIV mutations
AU751471B2 (en) Method and kit for evaluation of HIV mutations
AU8846898A (en) Method and kit for hla class i typing dna
GB2395008A (en) Method and kit for evaluation of HIV mutations
GB2395787A (en) Method and kit for evaluation of HIV mutations
WO2009098998A1 (en) Nucleic acid detection method, and nucleic acid detection kit
JP3030038B2 (en) Gene analysis method by liquid hybridization
Andersson et al. PCR and DNA sequencing
O'Meara Molecular tools for nucleic acid analysis
WO2004087964A1 (en) Method of detecting detecting mutations
JPWO2009054367A1 (en) Target DNA detection method and target DNA detection kit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER HEALTHCARE LLC

17Q First examination report despatched

Effective date: 20050127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060412